Infliximab
- Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies. van Schie et al., Ann Rheum Dis. 2017 Jul;76(7):1285-1288
- Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity. Plasencia et al., Clin Exp Rheumatol. 2016 Jul-Aug;34(4):655-62. Epub 2016 May 19.
- The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. van Schie et al., Ann Rheum Dis 2015; 74(1):311-4
- The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis. van den Bemt et al., Br J Clin Pharmacol. 2013 Dec;76(6):939-45.
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease. Afif et al., Am J Gastroenterol 2010 Feb 9.
- Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study. Bartelds et al., Ann Rheum Dis 2009 Jul 5.
